North America Nuclear Medicine Market - Strategic Insights and Forecasts (2026-2031)

The North American Nuclear Medicine Market is projected to surge at a CAGR of 14.8%, reaching USD 16.5 billion in 2031 from USD 8.28 billion in 2026.

Key Highlights

Market Overview

Cancer care remains the largest source of commercial demand. Healthcare providers are adopting nuclear medicine technologies because they provide functional information that conventional anatomical imaging often cannot deliver. PET and SPECT procedures are now integrated into treatment planning, disease staging, therapy monitoring, and recurrence detection across multiple cancer indications. The expansion of prostate cancer imaging, neuroendocrine tumor diagnostics, and Alzheimer's disease assessment has increased utilization of advanced radiopharmaceuticals.

Demand is distributed across a complex value chain that includes isotope producers, radiopharmaceutical manufacturers, nuclear pharmacies, imaging equipment suppliers, hospitals, and outpatient diagnostic centers. Value creation increasingly favors suppliers capable of controlling isotope production, radiopharmaceutical development, distribution logistics, and regulatory compliance. The short half-life of many isotopes requires highly coordinated manufacturing and delivery networks, creating barriers for new entrants.

Healthcare providers are placing greater emphasis on diagnostic accuracy, reimbursement certainty, isotope availability, and workflow efficiency when selecting nuclear medicine solutions. Purchasing decisions increasingly consider access to approved radiopharmaceuticals and reliable distribution infrastructure rather than imaging equipment specifications alone.

Key Market Indicators

Sources: Canadian Nuclear Association, Government of Canada, GE HealthCare disclosures.

Key Indicator: More than 40 million medical isotope procedures are performed globally each year.

Commercial Meaning: The large and recurring procedural base supports continued investment in isotope production, radiopharmaceutical development, and imaging infrastructure.

Market Drivers

Expansion of precision oncology diagnostics.

Prostate cancer, neuroendocrine tumors, lymphoma, and other oncology applications are increasing the use of PET imaging agents. The commercial success of PSMA-targeted imaging products demonstrates how precision diagnostics are becoming embedded within treatment pathways. Recent FDA approvals and pipeline expansion activities indicate continued investment in oncology-focused radiopharmaceuticals.

Suppliers are responding through investments in radiopharmaceutical manufacturing, isotope supply agreements, and expanded distribution capabilities. Higher utilization rates improve economics for hospitals and diagnostic providers while increasing recurring demand for imaging agents.

Growth of theranostics and targeted radiopharmaceutical therapies.

Theranostics combines diagnostic imaging and targeted radionuclide therapy using related molecular targets. This approach is expanding beyond prostate cancer into additional oncology indications. Industry organizations identify theranostics as one of the most important areas of future nuclear medicine development because it links diagnosis, treatment selection, and therapy monitoring within a single clinical pathway.

The commercial impact extends beyond imaging procedures. Suppliers can generate revenue from diagnostic agents, therapeutic isotopes, manufacturing services, and clinical support programs.

Increasing burden of cancer and neurological disorders.

Healthcare systems are expanding the use of molecular imaging to support earlier diagnosis and more accurate treatment decisions. PET imaging is increasingly used in neurodegenerative disease assessment and oncology management. Nuclear medicine provides functional information that complements CT and MRI, making it valuable in clinical situations where anatomical imaging alone is insufficient.

This demand driver supports both established tracers and newer disease-specific radiopharmaceuticals entering the market.

Investments in isotope production infrastructure.

Supply security has become a strategic concern across North America. Canada continues to invest in isotope production infrastructure through reactor-based and cyclotron-based production networks. Facilities operated by organizations such as TRIUMF and licensed isotope processors support regional and global isotope availability.

These investments reduce supply disruption risks and support commercialization of emerging radiopharmaceutical products.

Market Restraints and Challenges

Dependence on international isotope supply chains.

Many critical medical isotopes used in North America originate outside the United States. Industry sources indicate that commercial molybdenum-99, the precursor for technetium-99m, remains heavily dependent on international supply networks. Any disruption affecting production reactors, transportation routes, or trade flows can create shortages.

Hospitals, nuclear pharmacies, and radiopharmaceutical manufacturers bear the operational consequences of supply interruptions because many isotopes cannot be stockpiled.

Short half-life and complex distribution requirements.

Many isotopes decay rapidly and require highly coordinated production, processing, transportation, and administration schedules. TRIUMF notes that some medical isotopes have half-lives measured in hours rather than days. These characteristics increase logistics costs and limit geographic flexibility.

The challenge is particularly relevant for rural healthcare providers and facilities located far from production centers.

Regulatory approval and manufacturing compliance burdens.

Radiopharmaceutical development requires compliance with pharmaceutical, radiation safety, transportation, and manufacturing regulations. Regulatory review timelines can affect commercialization schedules. Recent FDA review extensions involving nuclear medicine products highlight the importance of manufacturing documentation and quality controls.

Smaller companies often face greater financial pressure because approval delays can postpone revenue generation while development costs continue.

Capacity constraints in high-growth PET applications.

PET procedure growth is outpacing capacity expansion in some regions. Industry data indicates rising utilization of existing PET systems, suggesting increasing pressure on imaging infrastructure.

Capacity constraints may affect scheduling, equipment replacement decisions, and radiopharmaceutical demand planning during the forecast period.

Major Segment Analysis

PET Market

The PET segment represents the most commercially important application category within the North American nuclear medicine market. Demand is supported by oncology imaging, neurological assessment, cardiovascular diagnostics, and expanding theragnostic applications. PET imaging offers higher sensitivity and quantitative capabilities than many conventional nuclear imaging procedures, making it increasingly important in precision medicine.

Hospitals and advanced diagnostic centers are the primary purchasers. Their buying criteria emphasize tracer availability, reimbursement support, image quality, workflow integration, and access to emerging clinical applications. The increasing use of PSMA-targeted imaging for prostate cancer and specialized tracers for neurodegenerative diseases has strengthened the segment's revenue profile.

Competitive activity within PET increasingly centers on radiopharmaceutical portfolios rather than imaging hardware alone. Suppliers that combine tracer development, isotope access, regulatory expertise, and distribution infrastructure are better positioned to capture value. Recent PET procedure growth also suggests continued investment in scanner upgrades and imaging capacity expansion.

Regional Analysis

United States

The United States accounts for the largest share of regional demand due to its extensive hospital network, advanced cancer care infrastructure, and strong radiopharmaceutical development activity. Approximately 20 million nuclear medicine procedures are performed annually, supported by thousands of healthcare facilities. PET imaging continues to record strong procedural growth across the country.

FDA approvals and reimbursement developments remain important market catalysts. Product innovation is concentrated in oncology, neurology, and theranostic applications.

Canada

Canada occupies a strategically important position within the isotope supply chain. Reactor facilities, cyclotron networks, isotope processors, and research institutions contribute to domestic and international supply. Canadian organizations continue to invest in both established and emerging isotope production technologies.

Commercial opportunities are concentrated in isotope production, export activities, and specialized radiopharmaceutical development.

Mexico

Mexico represents a smaller but expanding market. Demand is supported by improving healthcare infrastructure and growing access to advanced diagnostic technologies. Adoption remains concentrated in larger metropolitan healthcare systems, where access to nuclear medicine specialists and imaging facilities is strongest.

Other North America

Smaller markets benefit from regional isotope distribution networks and technology transfers originating from the United States and Canada. Market development depends on healthcare investment levels, specialist availability, and regulatory capacity.

Competitive Landscape

The North American nuclear medicine market exhibits characteristics of a technology-driven and supply-chain-intensive industry. Competitive advantage depends on isotope access, regulatory expertise, radiopharmaceutical development capabilities, distribution infrastructure, and clinical adoption support.

Major participants include Bracco, Cambridge Isotope Laboratories, Cardinal Health, FUJIFILM Holdings, GE HealthCare, Nordion, Taiyo Nippon Sanso Corporation, Lantheus Medical Imaging, Philips, and Digirad Corporation.

Competition increasingly favors companies capable of integrating radiopharmaceutical development with manufacturing and distribution. Lantheus has expanded its precision diagnostics portfolio and continues to invest in oncology imaging products. Cardinal Health benefits from its extensive nuclear pharmacy network, while GE HealthCare and Philips leverage installed imaging equipment bases and hospital relationships.

Barriers to entry remain high because participants must secure isotope supply, maintain regulatory compliance, establish specialized logistics capabilities, and build clinical acceptance among physicians and healthcare systems.

Recent Developments

• March 2026: The FDA approved Lantheus' Pylarify TruVu formulation for prostate cancer imaging. The approval increases production efficiency and may expand access to PSMA PET imaging across underserved regions.

• November 2025: Siemens Healthineers integrated PETNET Solutions and Advanced Accelerator Applications under its Radiopharma segment. The move unified one of North America’s largest radiopharmaceutical distribution networks, supporting nuclear medicine diagnostics and theranostics.

• April 2025: Iotron Medical joined the Canadian Nuclear Isotope Council to support commercialization of copper-67 isotope production. The development reflects continued investment in theranostic isotope supply chains.

• April 2025: Lantheus acquired Evergreen Theragnostics, gaining OCTEVY™, a late-stage PET imaging agent for neuroendocrine tumors, alongside radioligand therapy manufacturing infrastructure and a portfolio of theranostic development programs.

• January 2025: Telix finalized its acquisition of RLS (USA), adding a nationwide radiopharmacy network with more than 30 locations. The transaction strengthens radiopharmaceutical distribution and supports commercialization of nuclear medicine products.

Regulatory and Policy Environment

The regulatory framework governing nuclear medicine in North America combines pharmaceutical regulation, radiation safety oversight, isotope transportation rules, and healthcare reimbursement requirements. In the United States, the FDA regulates radiopharmaceutical approvals, while nuclear material handling falls under additional federal and state oversight.

Canada maintains a strong regulatory structure through the Canadian Nuclear Safety Commission, which licenses isotope production and processing facilities. Licensed facilities operated by organizations such as Nordion and BWXT Medical play an important role in maintaining isotope supply reliability.

Policy attention increasingly focuses on isotope supply resilience, domestic production capabilities, and support for emerging therapeutic isotopes. Governments and industry organizations view isotope availability as both a healthcare and strategic supply-chain issue.

Outlook and Strategic Implications

Demand growth during the forecast period is likely to be shaped by three factors: expansion of precision oncology, commercialization of theranostic therapies, and continued investment in isotope production capacity. These factors support growth across radiopharmaceuticals, imaging systems, and nuclear pharmacy services.

Several strategic implications warrant attention:

• Healthcare providers may need additional PET capacity as procedure volumes continue to increase.

• Radiopharmaceutical developers are likely to focus on targeted oncology and neurological applications.

• Isotope supply security will remain a priority for governments, manufacturers, and healthcare systems.

• Distribution networks capable of handling short-lived isotopes will become increasingly valuable.

• Regulatory expertise and manufacturing quality systems will remain important barriers to entry.

Commercial success will increasingly depend on controlling critical portions of the isotope-to-patient value chain. Companies that combine isotope access, radiopharmaceutical innovation, regulatory capabilities, and distribution infrastructure are expected to capture a larger share of market value as nuclear medicine expands from diagnostic imaging toward integrated precision therapy.

North America Nuclear Medicine Market Scope: